Symbols / IMRX
IMRX Chart
About
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 329.31M |
| Enterprise Value | 105.66M | Income | -62.50M | Sales | — |
| Book/sh | 3.59 | Cash/sh | 3.52 | Dividend Yield | — |
| Payout | 0.00% | Employees | 54 | IPO | — |
| P/E | — | Forward P/E | -3.38 | PEG | — |
| P/S | — | P/B | 1.42 | P/C | — |
| EV/EBITDA | -1.66 | EV/Sales | — | Quick Ratio | 23.84 |
| Current Ratio | 24.00 | Debt/Eq | 1.72 | LT Debt/Eq | — |
| EPS (ttm) | -1.79 | EPS next Y | -1.51 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-19 | ROA | -25.91% |
| ROE | -43.75% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 64.57M |
| Shs Float | 49.32M | Short Float | 20.08% | Short Ratio | 3.94 |
| Short Interest | — | 52W High | 10.08 | 52W Low | 1.10 |
| Beta | 0.46 | Avg Volume | 1.72M | Volume | 643.39K |
| Target Price | $17.17 | Recom | Strong_buy | Prev Close | $4.96 |
| Price | $5.10 | Change | 2.82% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$17.17
Mean price target
2. Current target
$5.10
Latest analyst target
3. DCF / Fair value
$-7.74
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.10
Low
$11.00
High
$30.00
Mean
$17.17
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-13 | main | Chardan Capital | Buy → Buy | $20 |
| 2025-10-31 | init | Leerink Partners | — → Outperform | $15 |
| 2025-09-30 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2025-09-26 | main | Chardan Capital | Buy → Buy | $20 |
| 2025-09-25 | main | Oppenheimer | Outperform → Outperform | $30 |
| 2025-09-15 | main | Needham | Buy → Buy | $11 |
| 2025-08-26 | reit | Needham | Buy → Buy | $8 |
| 2025-08-14 | main | Chardan Capital | Buy → Buy | $13 |
| 2025-06-18 | main | Mizuho | Outperform → Outperform | $10 |
| 2025-06-18 | reit | Needham | Buy → Buy | $9 |
| 2025-06-18 | main | Chardan Capital | Buy → Buy | $13 |
| 2025-06-05 | reit | Needham | Buy → Buy | $9 |
| 2025-05-07 | main | Oppenheimer | Outperform → Outperform | $21 |
| 2025-05-06 | main | Chardan Capital | Buy → Buy | $13 |
| 2025-04-10 | reit | Needham | Buy → Buy | $12 |
| 2025-03-24 | main | Chardan Capital | Buy → Buy | $13 |
| 2025-03-21 | reit | Needham | Buy → Buy | $12 |
| 2025-02-06 | reit | Needham | Buy → Buy | $12 |
| 2025-01-13 | reit | Needham | Buy → Buy | $15 |
| 2025-01-08 | main | Chardan Capital | Buy → Buy | $13 |
- $IMRX stock is up 22% today. Here's what we see in our data. - Quiver Quantitative Wed, 07 Jan 2026 08
- Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data (NASDAQ:IMRX) - Seeking Alpha hu, 08 Jan 2026 08
- We Think Immuneering (NASDAQ:IMRX) Can Afford To Drive Business Growth - Yahoo Finance hu, 27 Nov 2025 08
- Immuneering stock falls after reporting survival data for pancreatic cancer drug - Investing.com Wed, 07 Jan 2026 08
- Global trial to test drug combo for first-line pancreatic cancer patients - Stock Titan Wed, 17 Dec 2025 08
- Immuneering (IMRX) Valuation After Strong Phase 2a Pancreatic Cancer Data And Planned Phase 3 Transition - Yahoo Finance Sun, 11 Jan 2026 08
- $IMRX stock is down 12% today. Here's what we see in our data. - Quiver Quantitative Wed, 03 Sep 2025 07
- Immuneering plummets following phase 2 data of atebimetinib for pancreatic cancer - Seeking Alpha Wed, 07 Jan 2026 08
- Feinberg Peter buys Immuneering Corp (IMRX) shares for $52,730 - Investing.com Wed, 01 Oct 2025 07
- Immuneering (IMRX) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance Wed, 26 Nov 2025 08
- $IMRX stock is up 6% today. Here's what we see in our data. - Quiver Quantitative hu, 02 Oct 2025 07
- Wall Street Analysts See a 126.21% Upside in Immuneering (IMRX): Can the Stock Really Move This High? - Yahoo Finance Wed, 26 Nov 2025 08
- Positive Trial Data Supports 43% Upside for Immuneering Corporation (IMRX) - Yahoo Finance ue, 30 Sep 2025 07
- Immuneering Corporation Stock (IMRX) Opinions on Public Offering and Clinical Data - Quiver Quantitative Wed, 01 Oct 2025 07
- New Analyst Forecast: $IMRX Given $20.0 Price Target - Quiver Quantitative hu, 13 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 5250 | 24990 | — | Purchase at price 4.76 per share. | BRAKEWOOD HAROLD EUGENE | Officer | — | 2026-01-16 00:00:00 | D |
| 1 | 21645 | 101041 | — | Purchase at price 4.67 per share. | SCHALL THOMAS J | Director | — | 2026-01-15 00:00:00 | D |
| 2 | 2298 | 10502 | — | Purchase at price 4.57 per share. | HALL BRETT MATTHEW | Officer | — | 2026-01-15 00:00:00 | D |
| 3 | 2626 | 10906 | — | Purchase at price 4.15 per share. | NEUFELD LEAH R | Officer | — | 2026-01-13 00:00:00 | D |
| 4 | 20000 | 86904 | — | Purchase at price 4.35 per share. | FEINBERG PETER | Director | — | 2026-01-12 00:00:00 | I |
| 5 | 7500 | 50025 | — | Purchase at price 6.67 per share. | FEINBERG PETER | Director | — | 2025-10-03 00:00:00 | D |
| 6 | 1020 | 6966 | — | Purchase at price 6.83 per share. | BOOKMAN MICHAEL | Officer | — | 2025-10-01 00:00:00 | D |
| 7 | 300 | 1917 | — | Purchase at price 6.39 per share. | MORALES MALLORY | Officer | — | 2025-10-01 00:00:00 | D |
| 8 | 800 | 5103 | — | Purchase at price 6.38 per share. | NEUFELD LEAH R | Officer | — | 2025-10-01 00:00:00 | D |
| 9 | 7500 | 52730 | — | Purchase at price 7.03 per share. | FEINBERG PETER | Director | — | 2025-09-30 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.01 |
| NormalizedEBITDA | -63.69M | -58.06M | -51.47M | -33.73M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -61.04M | -53.47M | -50.51M | -33.54M |
| ReconciledDepreciation | 385.07K | 352.08K | 277.25K | 159.07K |
| ReconciledCostOfRevenue | 0.00 | 158.12K | 994.00K | |
| EBITDA | -63.69M | -58.06M | -51.47M | -33.73M |
| EBIT | -64.07M | -58.41M | -51.75M | -33.89M |
| NetInterestIncome | 2.59M | 3.61M | 1.01M | 169.90K |
| InterestIncome | 2.59M | 3.61M | 1.01M | 169.90K |
| NormalizedIncome | -61.04M | -53.47M | -50.51M | -33.54M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -61.04M | -53.47M | -50.51M | -33.54M |
| TotalExpenses | 64.07M | 58.41M | 52.06M | 35.97M |
| RentExpenseSupplemental | 108.00K | |||
| TotalOperatingIncomeAsReported | -64.07M | -58.41M | -51.74M | -33.89M |
| DilutedAverageShares | 29.98M | 28.42M | 26.39M | 13.61M |
| BasicAverageShares | 29.98M | 28.42M | 26.39M | 13.61M |
| DilutedEPS | -2.04 | -1.88 | -1.91 | -2.46 |
| BasicEPS | -2.04 | -1.88 | -1.91 | -2.46 |
| DilutedNIAvailtoComStockholders | -61.04M | -53.47M | -50.51M | -33.54M |
| NetIncomeCommonStockholders | -61.04M | -53.47M | -50.51M | -33.54M |
| NetIncome | -61.04M | -53.47M | -50.51M | -33.54M |
| NetIncomeIncludingNoncontrollingInterests | -61.04M | -53.47M | -50.51M | -33.54M |
| NetIncomeContinuousOperations | -61.04M | -53.47M | -50.51M | -33.54M |
| TaxProvision | 0.00 | -307.49K | ||
| PretaxIncome | -61.04M | -53.47M | -50.51M | -33.84M |
| OtherIncomeExpense | 441.49K | 1.33M | 216.84K | -127.06K |
| OtherNonOperatingIncomeExpenses | 441.49K | 1.33M | 216.84K | -127.06K |
| NetNonOperatingInterestIncomeExpense | 2.59M | 3.61M | 1.01M | 169.90K |
| InterestIncomeNonOperating | 2.59M | 3.61M | 1.01M | 169.90K |
| OperatingIncome | -64.07M | -58.41M | -51.75M | -33.89M |
| OperatingExpense | 64.07M | 58.41M | 51.90M | 34.81M |
| DepreciationAmortizationDepletionIncomeStatement | 29.27K | 29.27K | 30.05K | 0.00 |
| DepreciationAndAmortizationInIncomeStatement | 29.27K | 29.27K | 30.05K | 0.00 |
| Amortization | 29.27K | 29.27K | 30.05K | 0.00 |
| AmortizationOfIntangiblesIncomeStatement | 29.27K | 29.27K | 30.05K | 0.00 |
| ResearchAndDevelopment | 47.96M | 41.62M | 36.27M | 26.54M |
| SellingGeneralAndAdministration | 16.08M | 16.76M | 15.61M | 8.27M |
| GeneralAndAdministrativeExpense | 16.08M | 16.76M | 15.61M | 8.27M |
| OtherGandA | 4.08M | 4.90M | 5.41M | 2.83M |
| RentAndLandingFees | 125.00K | |||
| SalariesAndWages | 12.00M | 11.86M | 10.20M | 5.44M |
| GrossProfit | 0.00 | 158.83K | 926.89K | |
| CostOfRevenue | 0.00 | 158.12K | 1.15M | |
| TotalRevenue | 0.00 | 0.00 | 316.95K | 2.08M |
| OperatingRevenue | 0.00 | 0.00 | 316.95K | 2.08M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 31.05M | 29.27M | 26.42M | 26.32M |
| ShareIssued | 31.05M | 29.27M | 26.42M | 26.32M |
| TotalDebt | 4.16M | 4.46M | 4.84M | 5.36M |
| TangibleBookValue | 34.35M | 83.51M | 102.75M | 148.84M |
| InvestedCapital | 41.39M | 90.58M | 109.85M | 155.98M |
| WorkingCapital | 32.08M | 81.24M | 100.69M | 146.70M |
| NetTangibleAssets | 34.35M | 83.51M | 102.75M | 148.84M |
| CapitalLeaseObligations | 4.16M | 4.46M | 4.84M | 5.36M |
| CommonStockEquity | 41.39M | 90.58M | 109.85M | 155.98M |
| TotalCapitalization | 41.39M | 90.58M | 109.85M | 155.98M |
| TotalEquityGrossMinorityInterest | 41.39M | 90.58M | 109.85M | 155.98M |
| StockholdersEquity | 41.39M | 90.58M | 109.85M | 155.98M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | -778.00 | -30.12K | -49.01K |
| OtherEquityAdjustments | -778.00 | -30.12K | -49.01K | |
| RetainedEarnings | -224.30M | -163.26M | -109.79M | -59.27M |
| AdditionalPaidInCapital | 265.65M | 253.81M | 219.64M | 215.28M |
| CapitalStock | 31.05K | 29.27K | 26.42K | 26.32K |
| CommonStock | 31.05K | 29.27K | 26.42K | 26.32K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 11.33M | 12.01M | 12.52M | 10.72M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 3.82M | 4.16M | 4.46M | 5.09M |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 0.00 | ||
| LongTermDebtAndCapitalLeaseObligation | 3.82M | 4.16M | 4.46M | 5.09M |
| LongTermCapitalLeaseObligation | 3.82M | 4.16M | 4.46M | 5.09M |
| CurrentLiabilities | 7.50M | 7.85M | 8.05M | 5.63M |
| OtherCurrentLiabilities | 233.66K | 259.77K | 19.80K | |
| CurrentDebtAndCapitalLeaseObligation | 338.44K | 300.11K | 378.72K | 274.04K |
| CurrentCapitalLeaseObligation | 338.44K | 300.11K | 378.72K | 274.04K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 3.58M | 3.63M | 3.63M | 2.92M |
| PayablesAndAccruedExpenses | 3.35M | 3.66M | 4.02M | 2.44M |
| CurrentAccruedExpenses | 1.39M | 1.55M | 869.91K | 1.05M |
| Payables | 1.96M | 2.11M | 3.15M | 1.39M |
| AccountsPayable | 1.96M | 2.11M | 3.15M | 1.39M |
| TotalAssets | 52.71M | 102.58M | 122.37M | 166.70M |
| TotalNonCurrentAssets | 13.13M | 13.50M | 13.62M | 14.37M |
| OtherNonCurrentAssets | 1.30M | 1.03M | 743.70K | 102.13K |
| InvestmentsAndAdvances | 0.00 | 996.56K | ||
| OtherInvestments | 0.00 | 996.56K | ||
| InvestmentinFinancialAssets | 0.00 | 996.56K | ||
| AvailableForSaleSecurities | 996.56K | |||
| GoodwillAndOtherIntangibleAssets | 7.04M | 7.07M | 7.10M | 7.14M |
| OtherIntangibleAssets | 350.41K | 379.68K | 408.95K | 439.00K |
| Goodwill | 6.69M | 6.69M | 6.69M | 6.70M |
| NetPPE | 4.79M | 5.40M | 5.78M | 6.13M |
| AccumulatedDepreciation | -1.08M | -728.29K | -418.34K | -174.22K |
| GrossPPE | 5.87M | 6.12M | 6.20M | 6.31M |
| Leases | 298.94K | 298.94K | 288.91K | 152.12K |
| OtherProperties | 4.90M | 5.18M | 5.38M | 5.79M |
| MachineryFurnitureEquipment | 669.41K | 649.49K | 528.66K | 366.14K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 39.59M | 89.08M | 108.75M | 152.33M |
| OtherCurrentAssets | 3.44M | 3.42M | 3.21M | 2.89M |
| PrepaidAssets | 2.89M | |||
| Receivables | 0.00 | 12.42K | 246.04K | |
| AccountsReceivable | 0.00 | 12.42K | 246.04K | |
| CashCashEquivalentsAndShortTermInvestments | 36.14M | 85.67M | 105.52M | 149.20M |
| OtherShortTermInvestments | 0.00 | 26.26M | 32.89M | 74.31M |
| CashAndCashEquivalents | 36.14M | 59.41M | 72.64M | 74.89M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -55.08M | -49.31M | -44.84M | -30.91M |
| IssuanceOfCapitalStock | 4.24M | 28.20M | 0.00 | 145.11M |
| CapitalExpenditure | -84.88K | -342.75K | -742.48K | -60.79K |
| EndCashPosition | 36.14M | 59.41M | 72.64M | 74.89M |
| BeginningCashPosition | 59.41M | 72.64M | 74.89M | 37.09M |
| ChangesInCash | -23.26M | -13.23M | -2.25M | 37.80M |
| FinancingCashFlow | 5.30M | 28.44M | 19.00K | 144.26M |
| CashFlowFromContinuingFinancingActivities | 5.30M | 28.44M | 19.00K | 144.26M |
| NetOtherFinancingCharges | -40.99K | -203.77K | -281.38K | -2.12M |
| ProceedsFromStockOptionExercised | 1.11M | 444.84K | 300.38K | 1.28M |
| NetPreferredStockIssuance | 0.00 | 24.79M | ||
| PreferredStockIssuance | 0.00 | 24.79M | ||
| NetCommonStockIssuance | 4.24M | 28.20M | 0.00 | 120.32M |
| CommonStockIssuance | 4.24M | 28.20M | 0.00 | 120.32M |
| InvestingCashFlow | 26.43M | 7.30M | 41.83M | -75.62M |
| CashFlowFromContinuingInvestingActivities | 26.43M | 7.30M | 41.83M | -75.62M |
| NetInvestmentPurchaseAndSale | 26.52M | 7.64M | 42.57M | -75.63M |
| SaleOfInvestment | 31.93M | 52.30M | 92.68M | 0.00 |
| PurchaseOfInvestment | -5.41M | -44.66M | -50.10M | -75.63M |
| NetBusinessPurchaseAndSale | 0.00 | 70.35K | ||
| SaleOfBusiness | 0.00 | 70.35K | ||
| NetPPEPurchaseAndSale | -84.88K | -342.75K | -742.48K | -60.79K |
| PurchaseOfPPE | -84.88K | -342.75K | -742.48K | -60.79K |
| OperatingCashFlow | -55.00M | -48.97M | -44.10M | -30.85M |
| CashFlowFromContinuingOperatingActivities | -55.00M | -48.97M | -44.10M | -30.85M |
| ChangeInWorkingCapital | -925.38K | -974.64K | 1.72M | 900.42K |
| ChangeInOtherCurrentLiabilities | -326.21K | -138.75K | -106.59K | -80.85K |
| ChangeInOtherCurrentAssets | -261.34K | -290.74K | -360.20K | 0.00 |
| ChangeInPayablesAndAccruedExpense | -312.97K | -384.91K | 2.23M | 3.11M |
| ChangeInAccruedExpense | -200.83K | 721.99K | 474.57K | 3.24M |
| ChangeInPayable | -112.14K | -1.11M | 1.76M | -130.40K |
| ChangeInAccountPayable | -112.14K | -1.11M | 1.76M | -130.40K |
| ChangeInPrepaidAssets | -24.86K | -172.66K | -284.35K | -2.41M |
| ChangeInReceivables | 0.00 | 12.42K | 233.62K | 279.71K |
| ChangesInAccountReceivables | 0.00 | 12.42K | 233.62K | 279.71K |
| StockBasedCompensation | 6.50M | 5.73M | 4.06M | 1.80M |
| AssetImpairmentCharge | 328.38K | 412.06K | 519.54K | |
| AmortizationOfSecurities | -259.18K | -1.02M | -171.38K | 130.24K |
| DeferredTax | 0.00 | -307.49K | ||
| DeferredIncomeTax | 0.00 | -307.49K | ||
| DepreciationAmortizationDepletion | 385.07K | 352.08K | 277.25K | 159.07K |
| DepreciationAndAmortization | 385.07K | 352.08K | 277.25K | 159.07K |
| AmortizationCashFlow | 29.27K | 29.27K | 30.05K | 0.00 |
| AmortizationOfIntangibles | 29.27K | 29.27K | 30.05K | 0.00 |
| Depreciation | 355.81K | 322.82K | 247.20K | 159.07K |
| OperatingGainsLosses | 6.78K | 3.94K | 5.17K | |
| GainLossOnSaleOfPPE | 6.78K | 3.94K | 5.17K | 0.00 |
| NetIncomeFromContinuingOperations | -61.04M | -53.47M | -50.51M | -33.54M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for IMRX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|